肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
6期
368-371
,共4页
常保东%曹林升%张力%葛永超%邱晓辉%郑涛%郭全喜
常保東%曹林升%張力%葛永超%邱曉輝%鄭濤%郭全喜
상보동%조림승%장력%갈영초%구효휘%정도%곽전희
环氧合酶2%血管内皮生长因子%预后%免疫组织化学%肾肿瘤
環氧閤酶2%血管內皮生長因子%預後%免疫組織化學%腎腫瘤
배양합매2%혈관내피생장인자%예후%면역조직화학%신종류
Cyclooxygenase 2%Vascular endothelial growth factor%Prognosis%Immunohistochemistry%Clear cell renal cell carcinoma
目的 探讨环氧合酶-2(COX-2)、血管内皮生长因子(VEGF)表达与透明细胞性肾细胞癌(CCRCC)患者预后的关系.方法 应用免疫组织化学EnVision法检测80例CCRCC患者肿瘤组织和20例输尿管癌或肾盂癌患者正常肾组织中COX-2、VEGF的表达情况,结合临床病理参数分析二者与CCRCC患者预后的关系.结果 COX-2在CCRCC组织中的阳性表达率为65.00%(52/80),显著高于正常肾组织中的10.00%(2/20)(x2=7.760,P=0.021);VEGF在CCRCC中的阳性表达率为61.25%(49/80),高于正常肾组织中的20.00%(4/20)(x2=8-870,P=0.012).COX-2的表达和CCRCCTNM分期(x2=8.200,P=0.005)、组织学分级(x2=13.860,P=0.000)以及淋巴结转移(x2=6.050,P=0.001)有相关性,而与年龄(x2=0.560,P=0.663)和肿瘤大小(x2=0.700,P=0.528)无相关性;CCRCC组织中COX-2和VEGF的表达呈正相关(r=0.485,P<0.01).COX-2、VECF的表达和CCRCC患者预后相关(分别为x2=18.280,P=0.038;x2=6.420,P=0.042).结论 COX-2和VEGF在CCRCC组织中的表达与肿瘤的发生、发展及预后密切相关,可以作为CCRCC患者的预后指标.
目的 探討環氧閤酶-2(COX-2)、血管內皮生長因子(VEGF)錶達與透明細胞性腎細胞癌(CCRCC)患者預後的關繫.方法 應用免疫組織化學EnVision法檢測80例CCRCC患者腫瘤組織和20例輸尿管癌或腎盂癌患者正常腎組織中COX-2、VEGF的錶達情況,結閤臨床病理參數分析二者與CCRCC患者預後的關繫.結果 COX-2在CCRCC組織中的暘性錶達率為65.00%(52/80),顯著高于正常腎組織中的10.00%(2/20)(x2=7.760,P=0.021);VEGF在CCRCC中的暘性錶達率為61.25%(49/80),高于正常腎組織中的20.00%(4/20)(x2=8-870,P=0.012).COX-2的錶達和CCRCCTNM分期(x2=8.200,P=0.005)、組織學分級(x2=13.860,P=0.000)以及淋巴結轉移(x2=6.050,P=0.001)有相關性,而與年齡(x2=0.560,P=0.663)和腫瘤大小(x2=0.700,P=0.528)無相關性;CCRCC組織中COX-2和VEGF的錶達呈正相關(r=0.485,P<0.01).COX-2、VECF的錶達和CCRCC患者預後相關(分彆為x2=18.280,P=0.038;x2=6.420,P=0.042).結論 COX-2和VEGF在CCRCC組織中的錶達與腫瘤的髮生、髮展及預後密切相關,可以作為CCRCC患者的預後指標.
목적 탐토배양합매-2(COX-2)、혈관내피생장인자(VEGF)표체여투명세포성신세포암(CCRCC)환자예후적관계.방법 응용면역조직화학EnVision법검측80례CCRCC환자종류조직화20례수뇨관암혹신우암환자정상신조직중COX-2、VEGF적표체정황,결합림상병리삼수분석이자여CCRCC환자예후적관계.결과 COX-2재CCRCC조직중적양성표체솔위65.00%(52/80),현저고우정상신조직중적10.00%(2/20)(x2=7.760,P=0.021);VEGF재CCRCC중적양성표체솔위61.25%(49/80),고우정상신조직중적20.00%(4/20)(x2=8-870,P=0.012).COX-2적표체화CCRCCTNM분기(x2=8.200,P=0.005)、조직학분급(x2=13.860,P=0.000)이급림파결전이(x2=6.050,P=0.001)유상관성,이여년령(x2=0.560,P=0.663)화종류대소(x2=0.700,P=0.528)무상관성;CCRCC조직중COX-2화VEGF적표체정정상관(r=0.485,P<0.01).COX-2、VECF적표체화CCRCC환자예후상관(분별위x2=18.280,P=0.038;x2=6.420,P=0.042).결론 COX-2화VEGF재CCRCC조직중적표체여종류적발생、발전급예후밀절상관,가이작위CCRCC환자적예후지표.
Objective To investigate the expression of cyclooxgenase 2 (COX-2) and vascular endothelial growth factor (VEGF) in clear cell renal cell carcinoma (CCRCC) and their correlation with Prognosis. Methods EnVision immunohistochemistry was used to determine the expression of COX-2 and VEGF in 80 CCRCC tissues and 20 normal kidney tissues .The relationship between the above marks and prognosis were analyzed. Results The positive rates of COX-2[65.00 % (52/80) vs 10.00 % (2/20), x2= 7.760, P= 0.021]and VEGF[61.25 % (49/20) vs 20.00 (4/80),x2 = 8.870, P= 0.012]were much higher in CCRCC than those in normal kidney. The expression of COX-2 was correlated with TNM stage (x2 = 8.200,P =0.005), histological grade (x2 = 13.860, P = 0.000) and lymph node metastasis (x2 = 6.050, P = 0.001) in CCRCC, but not with age (x2 = 0.560, P = 0.663) and diameter of tumor (x2 = 0.700, P = 0.528). Both COX-2 expression and VEGF expression were associated significantly with prognosis in CCRCC (x2 = 18.280,P = 0.038;x2 = 6.420, P= 0.042, respectively). There was a positive correlation between COX-2 and VEGF in CCRCC (r =0.485, P < 0.01). Conclusion COX-2 is related to prognosis in CCRCC and can be used as prognostic indicators in patients.
